- Home
- PDM vs JANX Comparison
PDM vs JANX Comparison
Compare PDM & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | JANX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 890.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PDM | JANX |
|---|---|---|
| Price | $8.35 | $13.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $9.00 | ★ $57.36 |
| AVG Volume (30 Days) | 691.3K | ★ 1.7M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $565,372,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.46 | $12.80 |
| 52 Week High | $9.19 | $45.79 |
Technical Indicators
Market Signals| Indicator | PDM | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 41.55 |
| Support Level | $7.97 | $13.43 |
| Resistance Level | $8.43 | $15.04 |
| Average True Range (ATR) | 0.22 | 0.66 |
| MACD | -0.01 | 0.26 |
| Stochastic Oscillator | 49.70 | 41.26 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.